Related Experiment Video

Updated: Nov 21, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K

[Chediak Higashi syndrome with cytotoxic T-cell lymphoma: a case report]

S Huang1, H Q Sun2, H X Li1

  • 1Department of Hematology and Oncology, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou 450018, China.

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|January 15, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.2K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.6K

Related Experiment Videos

Last Updated: Nov 21, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.2K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.6K

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.1K

Articles linked to this work by shared authors, journal, and citation graph.

[Clinical characteristics of 125 hospitalized patients with thunderstorm asthma in Lanzhou].

Zhonghua nei ke za zhi·2026

[Impact of cumulative atherogenic index of plasma exposure on the risk of new-onset cardiovascular disease in middle-aged and young populations].

Zhonghua xin xue guan bing za zhi·2026

[Clinical features and fistula acoustic characteristics in maintenance hemodialysis patients with versus without diabetes mellitus].

Zhonghua yi xue za zhi·2026

Incommensurate Transverse Peierls Transition and Signature of Chiral Charge Density Wave in EuAl4.

Nature communications·2025

Cytosine base editor-mediated SOCS2 knockout promotes C2C12 cell differentiation via the PI3K/AKT/mTOR signaling pathway.

Functional & integrative genomics·2025

[The 512th case: fever, cough, acute kidney injury].

Zhonghua nei ke za zhi·2025

[Advances in single cell omics applications in mantle cell lymphoma].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

[Germline DDX41 mutations and myelodysplastic neoplasms].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

[The efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of 9 cases of relapsed/refractory diffuse large B-cell lymphoma after failing CAR-T cell therapy].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

[Clinical analysis of bendamustine combined with rituximab as first-line therapy for B-cell lymphoproliferative disorders other than follicular lymphoma].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

[Efficacy and safety of ivosidenib-based therapy in 16 patients with IDH1-mutated acute myeloid leukemia].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

[Exploring the feasibility and limitations of using large language model to interpret bibliometric findings: a case study in hemophilia gene therapy].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

Synchronous Multifocal Intraductal Tubulopapillary Neoplasm of the Pancreas Treated with Total Pancreatectomy: A Case Report.

Surgical case reports·2026

Intrapericardial Mature Cystic Teratoma.

Annals of thoracic surgery short reports·2026

PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity.

Nature·2026

Tuberculosis during JAK inhibitor or TNF-α inhibitors therapy: a disproportionality analysis from WHO pharmacovigilance database.

Thorax·2026

Guillain-Barré Syndrome Following the Administration of Tarlatamab in Extensive-stage Small Cell Lung Cancer: A Case Report with Pathological Confirmation.

Internal medicine (Tokyo, Japan)·2026

PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype.

Journal for immunotherapy of cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us